Otsuka Holdings Co Ltd 2024 IR
The report outlines Otsuka Holdings' financial and sustainability performance for the fiscal year ended December 31, 2023, highlighting its progress under the 3rd Medium-Term Management Plan and transition to the 4th plan. The company achieved record revenue of over 2 trillion yen, driven by its core Pharmaceutical and Nutraceutical businesses. Key sustainability achievements include a 36.1% reduction in Scope 1 and 2 CO2 emissions compared to 2017, and the addition of biodiversity to its environmental materiality. Otsuka also expanded its global access to tuberculosis treatments, providing delamanid to over 100,000 patients across 120 countries.
Company: Otsuka Holdings Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 92
Otsuka Holdings Co Ltd
Integrated Report
The report outlines Otsuka Holdings' financial and sustainability performance for the fiscal year ended December 31, 2023, highlighting its progress under the 3rd Medium-Term Management Plan and transition to the 4th plan. The company achieved record revenue of over 2 trillion yen, driven by its core Pharmaceutical and Nutraceutical businesses. Key sustainability achievements include a 36.1% reduction in Scope 1 and 2 CO2 emissions compared to 2017, and the addition of biodiversity to its environmental materiality. Otsuka also expanded its global access to tuberculosis treatments, providing delamanid to over 100,000 patients across 120 countries.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees